AzTrials
AzTrials

MelanomaPhase 2NCT05299580

"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

A Phase 2 study testing dabrafenib and Trametinib in people with Melanoma, run by Fondazione Melanoma Onlus at 16 sites in Italy.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

There is evidence from cohort studies and metanalysis that a shift from BRAFWT to BRAF mutated melanomas can occur (Colombino JCO 2012, Valchis EJC 2017). Based on previous studies we expect that 15% of tissue BRAF WT patients treated with anti PD-1 will become circulating free DNA BRAF (CfDNA BRAF) mutation-positive… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Melanoma
What is being tested?
dabrafenib and Trametinib
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
16 sitesItaly
Study dates
18 Feb 2021to 30 Mar 2023
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients of either sex aged ≥ 18 years;
  • Histologically confirmed stage III (unresectable) or stage IV melanoma;
  • Tissue BRAFWT signature and a molecular shift to circulating free DNA BRAF mutated positive melanomas upon progression to anti PD-1 therapy;
  • Tumor biopsy, if feasible, to confirm the BRAFV600 mutation at progression;
  • Previous adjuvant treatment, including checkpoint inhibitors anti CTLA-4, anti PD- 1/PDL-1 is allowed, except for stage IV (if completed at least 6 months prior to enrollment, and all related adverse events have either returned to baseline or stabilized). BRAF inhibitor treatment in adjuvant setting is not permitted;
  • Last previous treatment for metastatic disease MUST BE Anti-PD1 as single agent;
Show all 14Show fewer
  • Able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels;
  • Measurable disease by computed tomography (CT) or Magnetic Resonance Imaging (MRI) per RECIST 1.1 criteria;
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 2 (see Appendix II);
  • Female subjects of childbearing potential must have a negative pregnancy test result at baseline and must practice two highly effective methods of contraception for the duration of the study, EOT, at 30-day and 150-day safety follow up;
  • Sexually active males must agree to use effective contraception methods throughout treatment and for 150 days after stopping treatment and should not father a child in this period. A condom is required to be used by vasectomized men as well during intercourse in order to prevent delivery of the drug via semen;
  • Adequate baseline organ function
  • Life expectancy of at least 3 months;
  • Ability to understand study-related patient information and provision of written informed consent for participation in the study.

Who cannot join

  • Symptomatic brain metastases;
  • History of another malignancy, exception: subjects who have been disease-free for 3 years, (i.e. subjects with second malignancies that are indolent or definitively treated at least 3 years ago) or subjects with a history of completely resected nonmelanoma skin cancer;
  • A history or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy including:
  • Presence of predisposing factors to RVO or central serous retinopathy (e.g., uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, uncontrolled diabetes mellitus, or a history of hyperviscosity or hypercoagulability syndromes); or
  • Visible retinal pathology as assessed by ophthalmic examination that is considered a risk factor for RVO or central serous retinopathy such as: i. Evidence of new optic disc cupping; ii. Evidence of new visual field defects on automated perimetry; iii. Intraocular pressure >21 mmHg as measured by tonometry.
  • A history of clinically significant or active interstitial lung disease or pneumonitis;
Show all 23Show fewer
  • Any serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), psychiatric disorders, or other conditions that could interfere with the subject's safety, obtaining informed consent, or compliance with study procedures;
  • Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted);
  • A history or evidence of cardiovascular risk including any of the following:
  • Current LVEF < LLN;
  • A QT interval corrected for heart rate using the Bazett's formula >480 msec;
  • A history or evidence of current clinically significant uncontrolled arrhythmias; Exception: Subjects with atrial fibrillation controlled for > 30 days prior to enrollment are eligible;
  • A history (within 6 months prior to enrollment) of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty;
  • A history or evidence of current >= Class II congestive heart failure as defined by the New York Heart Association (NYHA) guidelines;
  • Treatment refractory hypertension defined as a blood pressure of systolic> 140 mmHg and/or diastolic > 90 mm Hg which cannot be controlled by antihypertensive therapy;
  • Patients with intra-cardiac defibrillators or permanent pacemakers;
  • Known cardiac metastases;
  • Abnormal cardiac valve morphology (> grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study). Subjects with moderate valvular thickening should not be entered on study;
  • Uncorrectable electrolyte abnormalities (e.g. hypokalaemia, hypomagnesaemia, hypocalcaemia), long QT syndrome or taking medicinal products known to prolong the QT interval.
  • Female subjects who are pregnant (positive pregnancy test), breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control;
  • Inability to regularly access site facilities for logistical or other reasons;
  • History of poor co-operation, non-compliance with medical treatment, or unreliability;
  • Participation in any interventional drug or medical device study within 30 days prior to treatment start.

Trial locations and contacts

16 sites in 1 country.

16 sites in 1 country

Italy16 sites

  • Azienda Ospedaliera Nazionale SS. Antonio e Biagio e C. Arrigo

    Alessandria

  • National Institute of Cancer

    Bari, 70124

  • Università degli Studi di Bari Aldo Moro

    Bari

  • AOU Sant'Orsola-Malpighi

    Bologna

  • ASST Spedali Civili Brescia

    Brescia

  • Azienda Sanitaria Ospedaliera S. Croce e Carle

    Cuneo

  • IRCCS San Martino - IST

    Genova, 16132

  • IRCCS - Istituto Scientifico Romagnolo per la Cura e lo Studio dei Tumori (I.R.S.T) S.r.l.

    Meldola, Forlì-Cesena, 47014

  • Fondazione I.R.C.C.S. Istituto Nazionale dei Tumori

    Milan, 20133

  • Azienda Ospedaliera Universitaria di Modena

    Modena

  • Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione Giovanni Pascale"

    Naples, 80131

  • Istituto Oncologico Veneto

    Padova, 35128

  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone

    Palermo

  • Istituto Nazionale Tumori Regina Elena

    Roma, 00144

  • Azienda Ospedaliera Universitaria - Città della Salute e della Scienza di Torino

    Torino

  • Azienda Ospedaliera Universitaria Integrata di Udine

    Udine

Other trials in Italy

About this study

There is evidence from cohort studies and metanalysis that a shift from BRAFWT to BRAF mutated melanomas can occur (Colombino JCO 2012, Valchis EJC 2017). Based on previous studies we expect that 15% of tissue BRAF WT patients treated with anti PD-1 will become circulating free DNA BRAF (CfDNA BRAF) mutation-positive and, at progression, they will be elegible to be treated with dabrafenib/trametinib. We aimed to design a clinical phase II trial in order to evaluate the activity of Dabrafenib and Trametinib in patients with Tissue BRAFWT signature and a molecular shift to circulating free DNA BRAF mutated positive melanomas upon progression to anti PD-1 therapy.

Conditions
Melanoma
Being tested
dabrafenib, Trametinib
Medical subject headings
Melanoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • dabrafenibDrug

    Dabrafenib 150 mg bid

  • TrametinibDrug

    Trametinib 2mg qd

Study groups in NCT05299580
Study groupRoleWhat they receive
single armExperimentalPatients will be treated with Dabrafenib 150 mg bid and Trametinib 2mg qd. Each cycle is 28 days and the treatment will be continued until documented disease progression, unacceptable toxicity, intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the subject, subject withdraws consent, pregnancy of the subject, noncompliance with trial treatment or procedure requirements, or administrative reasons.
Receives: Drug: dabrafenib; Drug: Trametinib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall Response Rate

    proportion of patients who have a partial or complete response to therapy; it does not include stable disease and is a direct measure of drug tumoricidal activity

    Measured: From day 1 up to 24 months Every 12 weeks

Secondary outcomes (4)

  1. Progression Free Survival (PFS)

    the time from the date of first administration of therapy and the date of evidence of progression or death

    Measured: From day 1 up to 24 months Every 12 weeks

  2. Overall Survival

    the time from the date of first administration of therapy and the date of death from any cause.

    Measured: from 28 days from baseline up to 24 months

  3. Safety - NCI CTC-AE (Version 5.0)

    Will be used to evaluate the clinical safety of the treatment in this study; patients will be assessed for AEs at each clinical visit and as necessary throughout the study.

    Measured: up to 24 months

  4. QoL

    the 30-item European Organisation for Research and Treatment of Care quality of life questionnaire

    Measured: From day 1 up to 24 months Every 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Mar 2022
  2. Study start18 Feb 2021
  3. Primary completion30 Mar 2023
  4. Study completion30 Mar 2023

Why it stopped: lack of enrollment

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05299580
Sponsor's protocol ID
BIO-TAILOR
Status last verified
Sep 2023
First submitted
23 Feb 2022
Last updated
14 Sep 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing dabrafenib and Trametinib in people with Melanoma, run by Fondazione Melanoma Onlus at 16 sites in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 14 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 16 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall Response Rate (time frame: From day 1 up to 24 months Every 12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05299580.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2023.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in